Alzamend Neuro is trading 6.59% up at $1.62 after announcing on August 20, 2026, that its AL001 Phase 1/2A resting-state fMRI findings were accepted for poster presentation at Neuroscience 2026.
- The company-specific announcement is the clearest catalyst.
- Broader biotechnology sentiment remains supportive following positive cancer-vaccine results.
- Broader equities are lower, while sector conditions have recently been volatile.